Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Company announcement – No. 32 / 2019 Update regarding registration of new shares for Zealand Pharma Copenhagen, September 10, 2019 – In reference to Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL)...
-
Company announcement – No. 31 / 2019 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, September 5, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04...
-
Company announcement – No. 30 / 2019 A total of 3,975,000 new shares (the "New Shares") have been subscribed for with expected gross proceeds of approx. DKK 559.6 million The private placement and...
-
Company announcement – No. 28 / 2019 Copenhagen, August 30, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the...
-
Press release – No. 19 / 2019 Copenhagen, August 29, 2019 – Zealand Pharma Chief Executive Officer Emmanuel Dulac will attend the Morgan Stanley 17th Annual Global Healthcare Conference on...
-
Company announcement – No. 27 / 2019 Copenhagen, August 28, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the...
-
Company announcement – No. 27 / 2019 Copenhagen, August 28, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the...
-
Press Release – No. 18 / 2019 Copenhagen, August 27, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the...
-
Company announcement – No. 26 / 2019 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, August 23, 2019 – Zealand Pharma A/S (“Zealand”)...
-
Company announcement – No. 25 / 2019 Zealand Pharma delivers strong clinical results during the first half of 2019 and accelerates commercial build-up in the U.S. Copenhagen, August 15, 2019 –...